Key Points for Decision Makers {#FPar1}
==============================

A high subjective proportion of 28-joint Disease Activity Score (DAS28-P) is associated with a good-to-moderate EULAR response at 6 months after initiating abatacept in a real-world setting.Decrease in DAS28-P is observed in the RA patients who had good-to-moderate EULAR response to abatacept.RA patients with relatively more subjective complaints should not be ignored or excluded from the initiation of abatacept.

Introduction {#Sec1}
============

Therapeutic strategies for the treatment of rheumatoid arthritis (RA) were diversified by the advent of various biologic agents, but predicting their response in individual patients remains a challenge in real-world clinical practice \[[@CR1]\]. To reduce trial and error when selecting a biologic agent, previous studies have attempted to identify clinical or biochemical markers to forecast good or poor response \[[@CR2], [@CR3]\]. One of the well-known examples of an association for good response to a particular biologic agent and its predictor is between rituximab and seropositivity status, either rheumatoid factor or anti-cyclic citrullinated peptide antibody (ACPA) \[[@CR4]\]. Seropositivity was also shown to have a similar association with abatacept, but not with tocilizumab \[[@CR5], [@CR6]\]. However, most of the other proposed predictors have not demonstrated strong enough evidence to support clinical decision-making, or are too complex to be used universally. Discovering easily accessible, cost-effective predictive markers for treatment response would, thus, be beneficial for both patients and healthcare systems.

Recently, patient-reported outcomes (PROs) have been globally applied as endpoints in clinical trials to measure disease activity in patients with RA \[[@CR7]\]. PROs are reliable in describing a patient's perspective and symptoms, but are not as efficient as biomarkers such as C-reactive protein or erythrocyte sedimentation rate (ESR) in reflecting objective inflammation \[[@CR8]\]. Considering that biologic agents aim to block specific inflammatory targets, their effect on PROs would be regarded as a relatively indirect outcome of biologic agents. However, recent studies have reported the role of PROs as predictors of objective outcomes, such as radiographic progression or therapeutic response to biologic agents \[[@CR9], [@CR10]\].

The patient-reported components of the 28-joint Disease Activity Score (DAS28) comprise tender joint count (TJC) and the global health visual analog scale (VAS-GH) \[[@CR11]\], the combination of which is termed DAS28-P \[[@CR12]\]. As these patient-reported components can be affected by non-inflammatory conditions, such as combined osteoarthritis or fibromyalgia \[[@CR12]--[@CR14]\], higher DAS28-P was suspected as a factor predicting poor response to biologic agents \[[@CR15]\]. However, a study by Jurgens et al. conversely showed, though without statistical significance, an unexpected decrease in DAS28-P in patients with good (DAS28 at endpoint ≤ 3.2 and improvement of DAS28 from baseline ≤ 1.2) or moderate (DAS28 at endpoint ≤ 5.1 and improvement of DAS28 from baseline \> 0.6 and ≤ 1.2; DAS28 at endpoint \> 3.2 and improvement of DAS28 from baseline ≤ 1.2) European League Against Rheumatism (EULAR) response compared with the non-response group, where treatment was mostly with tumor necrosis factor (TNF) inhibitors \[[@CR15], [@CR16]\].

Abatacept (cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin, CTLA4-Ig) is a selective co-stimulation modulator with an inhibitory effect on T lymphocytes via binding to human CD80 and CD86 cells on antigen-presenting cells \[[@CR16]\]. Biologic factors, such as ACPA positivity or number of specific circulating T cells, were reported as potential predictors of good therapeutic response to abatacept \[[@CR5], [@CR17]\], while previous clinical trials found that abatacept was associated with significant improvements in both conventional measures of disease activity and PROs \[[@CR18]\]. In this study, we aimed to evaluate whether baseline DAS28-P is a predictor of EULAR response to abatacept after 6 months' treatment in patients with RA.

Materials and Methods {#Sec2}
=====================

Patients {#Sec3}
--------

The study population was a prospective, observational, multicenter cohort of Korean patients with RA, who were followed up for a nationwide post-marketing surveillance study of abatacept from March 2010 to March 2016. All of the study subjects met the 1987 American College of Rheumatology criteria of RA \[[@CR19]\] and provided written informed consent. This study was reviewed and approved by the institutional and ethical review boards of the 40 participating hospitals, including Seoul National University Hospital (IRB No. 1206-051-414).

Clinical Assessment {#Sec4}
-------------------

Baseline characteristics included age, sex, seropositivity, disease duration, current comorbidities, previous history of disease-modifying antirheumatic drug (DMARD) use, and biologic agents. Injection route of abatacept was subcutaneous or intravenous. Collected components of DAS28 (TJC, VAS-GH, swollen joint count \[SJC\], and ESR) at 0 and 6 months were included for analysis, and DAS28 and DAS28-P, a contribution of subjective components of DAS28, were calculated by means of the following formulas \[[@CR11], [@CR12]\]. Achievement of the criteria for low disease activity (DAS28 \< 3.2) and for remission (DAS28 \< 2.6) was also evaluated for each patient \[[@CR11]\].$$\documentclass[12pt]{minimal}
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Statistical Methods {#Sec5}
-------------------

Univariate analysis including the Chi square test or Kruskal--Wallis test was conducted for each baseline characteristic variable versus three EULAR response criteria groups (good, moderate, and none). Correlation of baseline DAS28-P versus DAS28 or change of DAS28 for the initial 6-month treatment period was evaluated by scatter plot and Pearson's coefficient (PC). After stratifying the study subjects into the three EULAR response groups, the mean value of baseline DAS28-P, or change in DAS28-P, was compared by Student's *t* test. The last-observation-carried-forward (LOCF) method was used for imputation of missing data.

To evaluate baseline DAS28-P as a predictor of EULAR response to abatacept, a receiver operating characteristic (ROC) curve with area under the curve (AUC) was measured. A practical cut-off value to predict favorable response was derived from the ROC curve plus the maximum value for the sum of specificity and sensitivity. Including the cut-off value of DAS28-P, as well as variables from the univariate analysis with significance (*p* \< 0.05), logistic regression analysis was conducted to deduce the predictive power of each variable associated with a good-to-moderate (favorable) EULAR response to abatacept in the study population. Statistical analysis was performed using SPSS version 18.0 (IBM Corp., USA). Odds ratios (ORs) and 95% confidence intervals were calculated, and statistical significance was inferred when *p* \< 0.05.

Results {#Sec6}
=======

Baseline Characteristics {#Sec7}
------------------------

Overall, 529 patients were included for efficacy analysis in the post-marketing survey, and 341 adult patients with RA on newly initiated abatacept were included for analysis after applying a 6-month LOCF method (Fig. [1](#Fig1){ref-type="fig"}). The baseline characteristics of the study population were analyzed after stratification by EULAR response at 6 months (Table [1](#Tab1){ref-type="table"}). Mean age (55.5 years) and disease duration (5.46 years) at enrollment were not significantly different among good, moderate, and non-response groups. Proportion of seropositivity (95.3%), previous use of DMARDs (85.6%), and subcutaneous administration of abatacept (11.1%) also showed no difference among response groups. However, patients with fewer comorbidities, as listed in Table [1](#Tab1){ref-type="table"} (*p* = 0.035), and those who were naive to biologic agents (*p* = 0.018) had better response to abatacept. Baseline DAS28 was highest in the moderate response group and lowest in the non-response group (*p* = 0.003). The baseline DAS28-P, SJC, TJC, VAS-GH, and ESR were the variables that deviated substantially from normality when evaluated by the Kolmogorov--Smirnov test (*p* \< 0.05).Fig. 1Flow chart for selection of patients included in the final analysis. *RA* rheumatoid arthritisTable 1Baseline characteristics of the study populationTotal (*n* = 341)EULAR responseGood (*n* = 72)Moderate (*n* = 178)None (*n* = 91)*P* valueAge, years55.5 ± 12.653.3 ± 12.056.0 ± 12.056.4 ± 13.60.255 (K)Sex, female (%)283 (83.0)60 (83.3)145 (81.5)78(85.7)0.677 (C)Body weight, kg56.8 ± 9.057.1 ± 10.457.1 ± 9.056.0 ± 7.50.861 (K)Seropositivity (%) Double negativity16 (4.7)6 (8.3)3 (1.7)7 (7.7)0.145 (C) Single ACPA positivity28 (8.2)4 (5.6)16 (9.0)8 (8.8) Single RF positivity79 (23.2)16 (22.2)39 (21.9)24 (26.4) Double positivity218 (63.9)46 (63.9)120 (67.4)52 (57.1)Disease duration, years5.46 ± 4.645.54 ± 4.675.22 ± 4.305.87 ± 5.300.820 (K)Comorbidities (current) (%)251 (73.6)45 (62.5)133 (74.7)73 (80.2)0.035 (C) Hypertension93 (27.3)19 (26.4)50 (28.1)24 (26.4) Diabetes42 (12.3)5 (6.9)20 (11.2)17 (18.7) Renal disease11 (3.2)3 (4.2)5 (2.8)3 (3.3) Osteoporosis77 (22.6)17 (23.6)32 (18.0)28 (30.8) Interstitial lung disease23 (6.7)2 (2.8)18 (10.1)3 (3.3) Liver disease15 (4.4)3 (4.2)9 (5.1)3 (3.3) Sjogren's or sicca18 (5.3)4 (5.6)8 (4.5)6 (6.6) Fibromyalgia12 (3.5)2 (2.8)6 (3.4)4 (4.4)Previous DMARDs (%)292 (85.6)63 (87.5)148 (83.2)81 (89.0)0.379 (C) Methotrexate57 (16.7)18 (25.0)25 (14.0)14 (15.4) Leflunomide124 (36.4)17 (23.6)67 (37.6)40 (44.0) Hydroxychloroquine152 (44.6)37 (51.4)76 (42.7)39 (42.9) Sulfasalazine105 (30.8)26 (36.1)48 (27.0)31 (34.1) TNF inhibitors135 (39.6)23 (31.9)65 (36.5)47 (51.6) Tocilizumab9 (2.6)0 (0.0)3 (1.7)6 (6.6) Rituximab8 (2.4)1 (1.4)4 (2.3)3 (3.3)Route of abatacept injection, SQ (%)38 (11.1)9 (12.5)16 (9.0)13 (14.3)0.391 (C)Biologics exposure (%) Naive203 (59.5)48 (66.7)112 (62.9)43 (47.3) Experienced138(40.5)24 (33.3)66 (37.1)48 (52.7)0.018 (C)DAS285.95 ± 1.215.52 ± 0.896.23 ± 1.045.75 ± 1.57\<0.001 (K) TJC, median (IQR)8 (5--14)6.5 (4--10)9 (5--16)6 (3--14)0.006 (K) VAS-GH, median (IQR)70 (55--80)70 (50--80)77.5 (60--80)65 (50--80)0.005 (K) SJC, median (IQR)6 (3--10)6 (3--9.5)6 (4--10)5 (2--11)0.207 (K) ESR, median (IQR) (mm/h)50 (32--73)38.5 (26--53)55.5 (37--79)52 (32--78)\<0.001 (K)DAS28-P, median (IQR)0.43 (0.38--0.47)0.43 (0.40--0.47)0.44 (0.39--0.48)0.42 (0.36--0.46)0.039 (K)The data were expressed as mean ± standard deviation, median (IQR), or number (percentage)*ACPA* anti-cyclic citrullinated peptide antibody, *(C)* Chi square test, *DAS28* 28-joint Disease Activity Score, *DAS28*-*P* patient-reported component of DAS28, *DMARD* disease-modifying antirheumatic drug, *ESR* erythrocyte sedimentation rate, *EULAR* European League Against Rheumatism, *IQR* interquartile range, *(K)* Kruskal--Wallis test, *RF* rheumatoid factor, *SJC* swollen joint count, *SQ* subcutaneous, *TNF* tumor necrosis factor, *TJC* tender joint count, *VAS*-*GH* global health visual analog scale

Correlation Between DAS28-P and Therapeutic Response {#Sec8}
----------------------------------------------------

Baseline DAS28-P had modest positive correlation with baseline DAS28 (PC = 0.529, *p* \< 0.001) (Fig. [2](#Fig2){ref-type="fig"}a) and a weak negative correlation with a change in DAS28 (PC = − 0.275, *p* \< 0.001) (Fig. [2](#Fig2){ref-type="fig"}b). The patients with good or moderate EULAR response after 6 months had slightly higher baseline DAS28-P (median 0.43, interquartile range \[IQR\] 0.40--0.47; median 0.44, IQR 0.39--0.48, respectively) compared with the non-response group (median 0.42, IQR 0.36--0.46; *p* \< 0.05 vs both groups) (Fig. [3](#Fig3){ref-type="fig"}a). Differences in change of DAS28-P at 6 months were more prominent among good (median − 0.22, IQR − 0.30 to − 0.11) and moderate (median −0.08, IQR − 0.13 to − 0.04) responders compared with the non-response group (median −0.01, IQR − 0.03 to 0.02) (Fig. [3](#Fig3){ref-type="fig"}b). Therefore, good or moderate response to abatacept after 6 months was associated with higher baseline DAS28-P and a decrease in DAS28-P when compared to the non-response group.Fig. 2Correlations between **a** baseline DAS28-P and DAS28, and **b** baseline DAS28-P vs change in DAS28 (Δ DAS28), during the initial 6 months of abatacept treatment. *DAS28* 28-joint Disease Activity Score, *DAS28*-*P* patient-reported component of DAS28Fig. 3Comparison of medians (with interquartile range) of DAS28-P among the groups with good, moderate or no EULAR response after the initial 6 months of treatment. **a** Baseline DAS28-P; **b** change in DAS28-P (Δ DAS28-P). *DAS28* 28-joint Disease Activity Score, *DAS28*-*P* patient-reported component of DAS28, *EULAR* European League Against Rheumatism

Cut-Off Value of DAS28-P to Predict Therapeutic Response {#Sec9}
--------------------------------------------------------

An ROC curve was drawn to estimate the performance of DAS28-P as a predictor of good-to-moderate response to abatacept at 6 months, but the AUC was relatively low (0.590, *p* = 0.014) (Fig. [4](#Fig4){ref-type="fig"}). The best cut-off value of DAS28-P as a predictor of good-to-moderate response was 0.44, which represents the maximum value for the sum of specificity and sensitivity. Specificity (71.4%) of the cut-off value (0.44) was modest, but sensitivity (48.8%) was poor.Fig. 4Receiver operating characteristic curve of DAS28-P to predict good-to-moderate EULAR response to abatacept (area under the curve = 0.590, *p* = 0.014). *DAS28* 28-joint Disease Activity Score, *DAS28*-*P* patient-reported component of DAS28, *EULAR* European League Against Rheumatism

Multivariate Analysis for Predictive Factors of Favorable EULAR Response {#Sec10}
------------------------------------------------------------------------

Including the elicited cut-off value of baseline DAS28-P, binary logistic regression analysis was conducted with the variables that had shown significance in the univariate analysis excluding the components of DAS28 (SJC, TJC, VAS-GH, ESR) and DAS28 itself due to evident collinearity with DAS28-P. The presence of fibromyalgia was additionally included as it was reported to have an association with DAS28-P recently (Table [2](#Tab2){ref-type="table"}) \[[@CR20]\]. Therefore, naivety to biologic agents, comorbidity except fibromyalgia (absence vs presence), fibromyalgia alone (absence vs presence), and the cut-off (\> 0.44) value of DAS28-P were finally included variables for binary logistic regression. The Hosmer--Lemeshow test to measure the goodness of fit of this logistic regression model showed an adequate fit of the model to the data (*χ*^2^ = 8.092, *p* = 0.231).Table 2Binary logistic regression analysis to predict factors indicating good-to-moderate EULAR response to abatacept during the initial 6 months of treatmentVariables*β*SEOR (95% CI)*P* valueIntercept− 0.2180.6630.742Naive to biologic agents0.6700.2531.954 (1.190--3.211)0.008Comorbidity except fibromyalgia0.5280.3081.696 (0.927--3.102)0.087Fibromyalgia0.4120.6461.509 (0.425--5.353)0.524DAS28-P cut-off (\> 0.44)0.8550.2682.350 (1.390--3.974)0.001*CI* confidence interval, *DAS28* 28-joint Disease Activity Score, *DAS28*-*P* patient-reported component of DAS28, *EULAR* European League Against Rheumatism, *OR* odds ratio, *SE* standard error

As a result, baseline DAS28-P cut-off (0.44) was the strongest predictive factor for favorable (good-to-moderate) EULAR response to abatacept among the related variables (OR 2.350, *p* = 0.001). Being naive to biologic agents (OR 1.954, *p* = 0.008) was also associated positively with EULAR response. Comorbidities other than fibromyalgia and fibromyalgia alone were not significantly associated with favorable EULAR response.

Discussion {#Sec11}
==========

In this study, DAS28-P was evaluated as a predictor of EULAR response after 6 months of treatment with abatacept in patients with RA as part of post-marketing surveillance in Korea. Patients who had high DAS28-P value at baseline showed good-to-moderate (favorable) EULAR response after 6 months' use of abatacept. At first glance, higher DAS28-P could be recognized as more complaints of pain and fatigue, which are characteristics of fibromyalgia. That would be a reason why the previous study by Jurgens et al. initially set a hypothesis that high DAS28-P is associated with worse response to biologic agent \[[@CR15]\]. To interpret the findings of the current study, the actual meaning of the DAS28-P needs to be discussed. DAS28-P is not just an absolute sum of subjective complaints, but rather a measure of the contribution of subjective endpoints in the calculation of the DAS-28 (i.e., those complaints that can be affected by various kinds of discomfort other than joint pain). For example, higher burden of systemic or extra-articular inflammation of RA would be reflected as a higher DAS28-P because those manifestations could mainly affect VAS-GH. As abatacept restores immune tolerance by targeting T cells rather than neutralizing a single cytokine, it may potentially influence the disease more fundamentally than TNF inhibitors such as adalimumab, and contribute to improvement of VAS-GH. This would be concordant with the results of a phase IIIb trial of abatacept that showed better response of subjective pain or global assessment in the abatacept group compared to the adalimumab group \[[@CR21]\].

Compared to previous studies that have reviewed DAS28-P as a predictive factor for therapeutic response of a biologic agent \[[@CR3], [@CR15]\], distinctive features of this study were (1) real-world population (in Korea) that initiated biologic therapy, (2) statistical difference of DAS28-P values among the three EULAR response groups, and (3) the study of abatacept, which was not included in the previous studies. Since the data are from an observational post-marketing surveillance study, the characteristics of the patients and quality of data acquisition might be heterogeneous. However, the national health insurance system in Korea strictly regulates the use of biologic agents with specific indications, and requires precise evaluation of therapeutic response of each patient to determine whether to continue co-payment. Approximately 90% of the patients who were using biologic agents met the insurance requirement. Hence, patients included in this study share some characteristics, such as previous failure with two or more DMARDs for at least 6 months, or a high rate of seropositivity, which were required factors of specific reimbursement for Korean RA patients.

This study has a few limitations. First, the predictive power of DAS28-P in abatacept users cannot be generalized in all RA patients. Because all of the RA patients who enrolled in this study were reimbursed a significant portion of the cost for abatacept from the Korean National Health Insurance system, they had to meet strict criteria (DAS28 \> 5.1, failure with more than two kinds of DMARDs for 6 months). There was no comparator as this was a surveillance study for abatacept, and therefore, DMARD or other biologic agent users were not available for analysis. It is difficult to differentiate whether these observations on DAS28-P were unique to abatacept or a shared feature of improvement regardless of the therapeutic agent used. Applying DAS28-P as a predictive factor for response in a previously performed, randomized, placebo-controlled trial may reveal whether the marker was specific to a biologic agent. Second, though seropositivity was the most acknowledged predictive factor for therapeutic response of biologic agents, it was not demonstrated in this study. This phenomenon might be associated with the high portion of seropositivity (95.3%) in the patient pool, which would have arisen from the aforementioned strict health insurance policy in Korea. As evidence for this association, the cohort of a previous report described the correlation of seropositivity with response to abatacept, and it may have been possible to compare two groups by serostatus because of the lower seropositivity rates (65--75%) \[[@CR5]\]. Third, the long-term efficacy data after the initial 6 months are not available. In this study, 73.3% of patients achieved good-to-moderate EULAR response at 6 months. Real-world efficacy data from the Danish registry showed that the rate was similar (70%) at the same time point, but increasing trends in the rate of good-to-moderate EULAR response or DAS28 remission were still maintained up to 48 weeks \[[@CR22]\]. Predicting long-term response by baseline DAS28-P or by DAS28-P after baseline would be interesting topics for future research. Fourth, the cut-off value (0.44) of the DAS28-P derived from the ROC curve was still important in multivariate analysis, but was insufficiently sensitive (48.8%) and was not robust enough for clinical practice. It would be a real message of this study that there is no need to be reluctant to start abatacept because of the high subjective portion of patients with high disease activity.

We suggested DAS28-P as an easily accessible composite disease activity index reflecting subjective complaints, useful for predicting treatment response to abatacept. PROs, such as the Routine Assessment of Patient Index Data 3 (RAPID3), are well validated measurements of disease activity in RA patients, especially for clinical trials \[[@CR23], [@CR24]\]. Although PROs are more sophisticated measures of pain, function, and global health status than clinical measures, it is not easy to obtain such questionnaire-based PROs frequently in clinical practice. On the other hand, because DAS28-P is a component of DAS28 and a commonly used and well validated measure of disease activity in RA patients, it can be easily calculated by a clinician for his/her patient without incurring additional costs for biomarker laboratory testing, such as for ACPA, C-reactive protein, or ESR. It would be beneficial to evaluate DAS28-P data in a longitudinal, long-term follow-up study with other biologic agents or DMARDs, such as in insurance claim data. Validating concordance or interaction between other established PROs and DAS28-P can add more credibility for the use of DAS28-P as a unique disease activity index in RA patients.

Conclusions {#Sec12}
===========

In conclusion, DAS28-P, the subjective portion of DAS28, could predict response to abatacept. High baseline DAS28-P and a decrease at 6 months after treatment initiation were associated with a favorable (good-to-moderate) EULAR response.
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